- Home
- CELU vs PRLD Comparison
CELU vs PRLD Comparison
Compare CELU & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- PRLD
- Stock Information
- Founded
- CELU 2016
- PRLD 2016
- Country
- CELU United States
- PRLD United States
- Employees
- CELU N/A
- PRLD N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- CELU Health Care
- PRLD Health Care
- Exchange
- CELU Nasdaq
- PRLD Nasdaq
- Market Cap
- CELU 49.9M
- PRLD 53.4M
- IPO Year
- CELU N/A
- PRLD 2020
- Fundamental
- Price
- CELU $2.24
- PRLD $0.91
- Analyst Decision
- CELU
- PRLD Buy
- Analyst Count
- CELU 0
- PRLD 3
- Target Price
- CELU N/A
- PRLD $4.33
- AVG Volume (30 Days)
- CELU 231.0K
- PRLD 455.0K
- Earning Date
- CELU 11-07-2024
- PRLD 11-06-2024
- Dividend Yield
- CELU N/A
- PRLD N/A
- EPS Growth
- CELU N/A
- PRLD N/A
- EPS
- CELU N/A
- PRLD N/A
- Revenue
- CELU $48,200,000.00
- PRLD $3,000,000.00
- Revenue This Year
- CELU N/A
- PRLD N/A
- Revenue Next Year
- CELU $233.89
- PRLD N/A
- P/E Ratio
- CELU N/A
- PRLD N/A
- Revenue Growth
- CELU 225.94
- PRLD N/A
- 52 Week Low
- CELU $1.30
- PRLD $0.80
- 52 Week High
- CELU $7.97
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- CELU 46.60
- PRLD 37.34
- Support Level
- CELU $2.17
- PRLD $0.80
- Resistance Level
- CELU $2.43
- PRLD $1.13
- Average True Range (ATR)
- CELU 0.26
- PRLD 0.09
- MACD
- CELU -0.01
- PRLD 0.02
- Stochastic Oscillator
- CELU 54.02
- PRLD 32.82
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.